

Clinical Trial Protocol

Iranian Registry of Clinical Trials

13 Jun 2026

Effect of intratracheal budesonide with surfactant in management of respiratory distress syndrome for prevention of bronchopulmonary dysplasia in preterm infants

Protocol summary

Study aim

Determination of efficacy of budesonide with surfactant administration in respiratory distress syndrome for prevention of bronchopulmonary dysplasia

Design

preterm infants that met inclusion criteria, randomly allocated in two groups. In control group, neonates receive initial dose of curosurf 2.5cc/kg intratracheally. Patients in intervention group receive budesonide 0.25 mg/kg in addition to intratracheal curosurf with same initial dose. We follow all neonates till discharge with respect to need for second doses of surfactant at first 3 days of life, reintubation in first 3 days after extubation and duration of supplemental oxygen therapy.

Settings and conduct

Preterm newborn infants who have respiratory distress syndrome will randomly allocate in control group (surfactant) or intervention group (surfactant plus budesonide) by random numbers generated by computerized random number generator in closed envelopes. Physician administer the drug in prepared syringes. A nurse who record the patients data will be blind to infant's group. Managing physician is blind about patients groups.

Participants/Inclusion and exclusion criteria

Inclusion criteria: preterm infants with gestation age 26-30 weeks and birth weight less than 1250 that have RDS and need to treat with surfactant Exclusion criteria: birth asphyxia, severe congenital anomalies, shock and cardiovascular instability

Intervention groups

In control group, patients receive intratracheal surfactant (Curosurf) with initial dose of 2.5 cc/kg; In intervention group, patients receive budesonide 0.25 mg/kg in addition to surfactant (Curosurf)

Main outcome variables

need to second doses of surfactant at first 3 days of life ,

need to reintubation in first 3 days after extubation ,
bronchopulmonary dysplasia

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20100512003915N20**

Registration date: **2018-07-07, 1397/04/16**

Registration timing: **registered_while_recruiting**

Last update: **2018-07-07, 1397/04/16**

Update count: **0**

Registration date

2018-07-07, 1397/04/16

Registrant information

Name

Manizheh Mostafa Gharehbaghi

Name of organization / entity

Tabriz University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 41 1526 2253

Email address

peirovifara@tbzmed.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2018-04-16, 1397/01/27

Expected recruitment end date

2018-08-22, 1397/05/31

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Effect of intratracheal budesonide with surfactant in management of respiratory distress syndrome for prevention of bronchopulmonary dysplasia in preterm infants

Public title

Administration of budesonide with surfactant and prevention of bronchopulmonary dysplasia

Purpose

Prevention

Inclusion/Exclusion criteria**Inclusion criteria:**

gestation age 26-30 weeks birth weight less than 1250 grams respiratory distress syndrome

Exclusion criteria:

5 minute Apgar score less than 4 congenital heart disease except patent ductus arteriosus and atrial septal defect necrotizing enterocolitis major congenital anomalies, esophageal atresia, diaphragmatic hernia chromosomal anomalies shock

Age

From **1 day** old to **3 days** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Care provider
- Outcome assessor
- Data analyser

Sample size

Target sample size: **128**

Randomization (investigator's opinion)

Randomized

Randomization description

newborn infants who met study criteria randomly allocate in two groups (surfactant and surfactant with budesonide) based on generated random number list

Blinding (investigator's opinion)

Double blinded

Blinding description

infants don't know the used drugs. clinical manager administer prepared drug according patients code. outcome is recorded by a nurse who is not aware administered drugs . researcher is blind about patients groups and records data

Placebo

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethic Committee of Tabriz University of Medical Sciences

Street address

Tabriz University of Medical Sciences. Gholgasht St.

City

Tabriz

Province

East Azarbaijan

Postal code

513866449

Approval date

2018-04-16, 1397/01/27

Ethics committee reference number

IR. TBZMED.REC.1397.041

Health conditions studied**1****Description of health condition studied**

Respiratory distress syndrome of newborn

ICD-10 code

P22.0

ICD-10 code description

Respiratory distress syndrome of newborn

Primary outcomes**1****Description**

Reintubation in first 3 days after extubation

Timepoint

We evaluate the neonate immediately after intervention and daily till 3 days after intervention and extubation

Method of measurement

tracheal reintubation

2**Description**

need to second doses of surfactant

Timepoint

Daily till day 3 of birth and 3 days after intervention

Method of measurement

surfactant administration

3**Description**

Bronchopulmonary dysplasia

Timepoint

Daily till 28 days after birth and day 28 after intervention
Method of measurement
need to supplemental oxygen

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: neonates receive budesonide 0.25 mg/kg in addition to intratracheal surfactant

Category

Treatment - Drugs

2

Description

Control group: neonates receive intratracheal surfactant 2.5 cc/kg (crusurf₉, Chessia, Italy)

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Al Zahra Hospital

Full name of responsible person

Dr Manizheh Mostafa Gharehbaghi

Street address

South Artesh St.

City

Tabriz

Province

East Azarbaijan

Postal code

513866449

Phone

+98 41 3553 9161

Email

gharehbaghimm@yahoo.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Dr Mohammad Barzegar

Street address

Gholgasht St.

City

Tabriz

Province

East Azarbaijan

Postal code

513866449

Phone

+98 41 3335 7310

Email

research-vice@tbzmed.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Tabriz University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Manizheh Mostafa Gharehbaghi

Position

professor

Latest degree

Subspecialist

Other areas of specialty/work

Pediatrics

Street address

South Artesh St.

City

Tabriz

Province

East Azarbaijan

Postal code

513866449

Phone

+98 41 3553 9161

Email

gharehbaghimm@yahoo.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Manizheh Gharehbaghi

Position

professor

Latest degree

Subspecialist

Other areas of specialty/work

Pediatrics

Street address

South Artesh St.

City

Tabriz

Province

East Azarbaijan

Postal code

513866449

Phone

+98 41 3553 9161

Email

gharehbaghimm@yahoo.com

Street address

South Artesh St.

City

Tabriz

Province

East Azarbaijan

Postal code

513866449

Phone

+98 41 3553 9161

Email

gharehbaghimm@yahoo.com

Person responsible for updating data**Contact****Name of organization / entity**

Tabriz University of Medical Sciences

Full name of responsible person

Manizheh Gharehbaghi

Position

professor

Latest degree

Subspecialist

Other areas of specialty/work

Pediatrics

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

There is no further information

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

No - There is not a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

No - There is not a plan to make this available